SYNTAXBIO
SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
SYNTAXBIO
Industry:
Biotechnology Medical Product Research
Founded:
2018-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Status:
Active
Similar Organizations
Enclara Pharmacia
Enclara Pharmacia offers clinical services, operation processes, and educational programs to improve patient care.
ExpressCells
ExpressCells creates custom cell lines for biological research and drug discovery.
National Institutes of Health
National Institutes of Health is a biomedical research facility that focuses on biomedical and health-related research.
Protein Fluidics
Protein Fluidics develops a biological assay for 3D cell models, organoids or spheroids to achieve multifunctional profiling.
TalexMedical
The proud producer of Infantear – a revolutionary Class I medical device for the treatment of external ear deformities in newborns.
The Jackson Laboratory
The Jackson Laboratory conducts mammalian genetics research offering scientific services and resources to laboratories and students.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
More informations about "SyntaxBio"
Home | Syntax Bio
Syntax Bio is a preclinical-stage biotech company overcoming the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation. top of page. Our Investors. ... - Cell Therapy Development …See details»
SyntaxBio - Crunchbase Company Profile & Funding
SyntaxBio has 6 investors including Illumina Ventures and EGB Capital. When was the last funding round for SyntaxBio? SyntaxBio closed its last funding round on Sep 17, 2024 from a …See details»
Syntax Bio - LinkedIn
Syntax Bio is a preclinical-stage biotech company, overcoming longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation. Skip to main ...See details»
Syntax Bio Launches with Strategic Backing from Astellas Venture ...
Sep 17, 2024 Syntax Bio is a preclinical-stage biotechnology company based in Chicago that is focused on generating therapeutic-grade cells from stem cells leveraging its novel Cellgorithm …See details»
Syntax Bio 2025 Company Profile: Valuation, Funding & Investors
Syntax Bio General Information Description. Operator of a cell therapy company intended to generate the diversity of all cells in the body. The company's modified clustered regularly …See details»
Contact | syntax-site
Reach out, share a question or provide feedback on our products. fill out the form and we’ll respond as soon as possible.See details»
Syntax Bio Introduces Advanced Technology in Cell Therapy
Sep 17, 2024 A defining feature of Syntax Bio’s technology is its capacity to accelerate cell differentiation, leading to a substantial reduction in the time needed to produce valuable cell …See details»
Syntax Bio Emerges with Innovative Cell Therapy Platform
Sep 19, 2024 Co-founded by Dr. Ryan Clarke and Professor Brad Merrill from the University of Illinois at Chicago, Syntax Bio’s platform has attracted attention for its potential to overcome …See details»
Seed Round - SyntaxBio - 2024-09-17 - Crunchbase
Organization Name . SyntaxBio . Announced Date Sep 17, 2024; Funding Type Seed; Funding Stage Seed; Lead Investors. ... sdbn.org — Syntax Bio Launches with Strategic Backing from …See details»
SyntaxBio - Products, Competitors, Financials, Employees, …
About SyntaxBio. SyntaxBio is a biotechnology company. It develops a genetic programming platform that programs cells without the need for consistent external intervention. It was …See details»
SyntaxBio - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Sep 17, 2024: Seed Round - …See details»
DCVC | Syntax Bio
Syntax Bio invented a faster way: it uses transient plasmids to carry CRISPR-mediated instructions for activating and repressing key genes directly into cells, accelerating …See details»
Syntax Bio - BIO International Convention 2025
Syntax Bio's regenerative medicine discovery platform overcomes the longstanding challenges in stem cell derived therapies by directly controlling and accelerating iPSC differentiation. A …See details»
Syntax Bio Launches with Strategic Backing from Astellas
Sep 17, 2024 By accelerating cell differentiation, Syntax Bio’s technology significantly reduces the time required to generate high-value cell types, overcoming longstanding challenges in …See details»
Syntax Bio Raises Funding | citybiz
Sep 18, 2024 To date, Syntax Bio has raised $15m to advance its cell differentiation discovery platform. Co-founded by Ryan Clarke, PhD, and Professor Brad Merrill, PhD, from the …See details»
SyntaxBio - Crunchbase
SyntaxBio develops genetic programming platform that can program cells without the need for consistent external intervention. New. Resources. ... Experience the new Crunchbase, …See details»
Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy ...
Notice: Most of the content on this page is produced by third party media organizations and is subject to individual copyright. We do not claim ownership to any content published by another …See details»
Syntax Bio Launches with Strategic Backing from Astellas Venture ...
Sep 17, 2024 CHICAGO–(BUSINESS WIRE)–Syntax Bio, a preclinical-stage biotechnology company, has launched with backing from Astellas Venture Management LLC and Illumina …See details»
Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy ...
Sep 24, 2023 Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. …See details»
SyntaxBio – XLerateHealth
SyntaxBio™ is a genetic platform that can program populations of cells without the need for consistent external intervention. Linkedin-in SyntaxBio (Chicago, IL) is developing a …See details»